Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities

• Published in: Nature reviews. Drug discovery Vol. 21; no. 7; pp. 529 - 540
• Main Authors: Kim, Tae Kon, Vandsemb, Esten N., Herbst, Roy S., Chen, Lieping
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.07.2022; Nature Publishing Group
• Subjects: 631/67; 692/308/153; 692/699/67/1059/2325; Antibodies; Antigens; Apoptosis; Biomedical and Life Sciences; Biomedicine; Biotechnology; Cancer Research; Clinical trials; Drug development; Immunotherapy; Ligands; Lung cancer; Lymphocytes; Medical research; Medicinal Chemistry; Melanoma; Molecular Medicine; Perspective; Pharmacology/Toxicology; Tumors
• ISSN: 1474-1776; 1474-1784
• DOI: 10.1038/s41573-022-00493-5

Tumours employ various tactics to adapt and eventually resist immune attack. These mechanisms are collectively called adaptive immune resistance (AIR). The first defined and therapeutically validated AIR mechanism is the selective induction of programmed cell death 1 ligand 1 (PDL1) by interferon-γ in the tumour. Blockade of PDL1 binding to its receptor PD1 by antibodies (anti-PD therapy) has resulted in remission of a fraction of patients with advanced-stage cancer, especially in solid tumours. However, many clinical trials combining anti-PD therapy with other antitumour drugs conducted without a strong mechanistic rationale have failed to identify a synergistic or additive effect. In this Perspective article, we discuss why defining AIR mechanisms at the tumour site should be a key focus to direct future drug development as well as practical approaches to improve current cancer therapy. This Perspective article discusses the mechanisms used by tumours to evade the immune system, collectively called adaptive immune resistance (AIR), and why defining AIR mechanisms in the tumour microenvironment is key in immunotherapy development.